Dendright is a private Australian Biotech Company based in Brisbane, Queensland. We are developing vaccines based on Dendritic cells to suppress autoimmune diseases.

The company’s major shareholder is UniQuest Pty Ltd, the main commercialisation company at The University of Queensland, Brisbane. Dendright Pty Ltd has secured funding from the Queensland Government’s Innovation Start-up Scheme and from the Australian Government’s Biotechnology Innovation Fund to progress preclinical development of the Dendritic cell technology and to conduct a Phase I clinical trial.

Dendright Pty Ltd is seeking further investment for its current clinical development programme, as well for the application of the technology in other autoimmune disease areas.

The technology is protected by a US patent application and is at the PCT stage.